Lupus Patients in England Achieve Remission with Pioneering GM Therapy
The Breakthrough in Lupus Treatment
Five lupus patients in England are in remission after being treated with a revolutionary therapy that genetically modifies their own cells, in a medical breakthrough that could offer people a cure, doctors have said.
Understanding CAR T-cell Therapy
CAR (chimeric antigen receptor) T-cell therapy involves removing a type of white blood cell also called T lymphocytes, which are crucial for hunting out infected or damaged cells, and engineering them to spot and destroy disease. The T-cells are then fed back into the patient via an infusion to reset their immune system.
The NHS Trial
In an NHS trial led by University College London hospitals foundation trust (UCLH) and University College London (UCL), nine patients with severe lupus were recruited. They had not previously responded to any treatments. Most had lupus nephritis, a serious complication involving the kidneys.
- Six patients received a lower dose of CAR-T and three got a higher dose.
- Five of those on the lower dose, who were followed up for an average of 11 months, went into remission within just a few months.
The Impact on Patients
One of the five patients, Katie Tinkler, said she no longer had any of the main symptoms of the disease more than three decades after her diagnosis. She has also skied for the first time in a decade and was able to dance at her daughter’s wedding.
The Future of Lupus Treatment
Prof Karl Peggs, the director of UCLH’s biomedical research centre, said that while larger studies were needed, CAR T-cell therapy could offer people the chance of a cure. “These findings are truly groundbreaking and offer fresh hope to people living with lupus,” he said.